Product Name:

NebuPeptide™ Semaglutide (Peptide Reference)

Catalog Number:

NBS-233755

Description:

NebuPeptide™ Semaglutide (Peptide Reference)(CAT#NBS-233755) is synthesized in accordance with the Semaglutide sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Semaglutide reference peptide ranging from milligrams to kilograms.

Peptide Name:

Semaglutide

Background:

Semaglutide (NNC 0113-0217; NNC-0113-0217; Ozempic) is a novel and potent agonist of glucagon-like peptide-1 (GLP-1) receptor and belongs to the long-acting GLP-1 analogue. It is authorized for use in the management of type 2 diabetes. Liraglutide, an agonist of the glucagon-like peptide-1 (GLP-1) receptor, likewise demonstrated strong neuroprotective effects in animal models of Parkinson's disease. Furthermore, PD patients benefiting from the GLP-1 mimetic exendin-4 have demonstrated positive protective effects in a phase II clinical trial.

Alias:

NN 9535; NN9535; NN-9535; Ozempic; NNC 0113-0217; NNC-0113-0217; NNC0113-0217; Semaglutide; Ozempic; Rybelsus; NN9535; UNII-53AXN4NNHX; Wegovy; NN 9535;

CAS Number:

910463-68-2

Formula:

C187H291N45O59

Molecular Weight:

4113.6

Purity:

see COA

Solubility:

see COA

Storage & Shipment:

Store at -20℃; ship with blue ice.

For R&D use only!

To get more information, please contact us freely.